Anna Ozaki
Overview
Explore the profile of Anna Ozaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamoto A, Kessoku T, Ogata T, Jono T, Takahashi K, Tanaka K, et al.
Diagnostics (Basel)
. 2024 Aug;
14(15).
PMID: 39125503
Although handheld ultrasound devices (HUDs) are commonplace, their ability to diagnose fecal retention (FR) remains unclear. This prospective observational study examined HUDs' usefulness in diagnosing FR in patients with constipation...
2.
Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Kobayashi T, et al.
Hepatol Commun
. 2023 Oct;
7(11).
PMID: 37902528
Background: Cholesterol levels and bile acid metabolism are important drivers of metabolic dysfunction-associated steatohepatitis (MASH) progression. Using a mouse model, we investigated the mechanism by which cholesterol exacerbates MASH and...
3.
Tanaka K, Ohkubo H, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, et al.
J Neurogastroenterol Motil
. 2023 Jul;
29(3):378-387.
PMID: 37417265
Background/aims: Natural history of chronic intestinal pseudo-obstruction (CIPO), a rare disease characterized by episodes of non-mechanical obstruction, is unclear in adults. This study evaluates the clinical course of CIPO and...
4.
Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Yamamoto A, et al.
JGH Open
. 2022 Oct;
6(10):696-703.
PMID: 36262543
Background And Aim: Non-alcoholic fatty liver disease (NAFLD) can progress in non-obese patients as in obese patients. Reports on long-term prognosis in non-obese NAFLD patients are controversial. Therefore, we aimed...
5.
Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Yamamoto A, et al.
BMJ Open
. 2022 Jul;
12(7):e060335.
PMID: 35820743
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome phenotype in the liver and thus obviously associated with metabolic abnormalities, including insulin resistance-related to hyperglycaemic and hyperlipidaemia. The prevalence...
6.
Yamamoto A, Kessoku T, Tanaka K, Takahashi K, Kasai Y, Ozaki A, et al.
Contemp Clin Trials Commun
. 2022 Jul;
28:100958.
PMID: 35812817
Background: Approximately 60% of patients with chronic constipation (CC) have a significantly higher rate of loss of defecation desire (LODD). Bile acids are expected to have a restorative effect on...
7.
Tanaka K, Kessoku T, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, et al.
BMJ Open
. 2022 May;
12(5):e060704.
PMID: 35636802
Introduction: Chronic constipation (CC) is a functional disorder that negatively impacts the quality of life of patients. This is a protocol for a multicentre, 12-week, randomised, double-blind, placebo-controlled study to...
8.
Kasai Y, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Kobayashi T, et al.
Clin Transl Gastroenterol
. 2022 May;
13(7):e00503.
PMID: 35616321
Introduction: No reports on both blood and fecal bile acids (BAs) in patients with nonalcoholic fatty liver disease (NAFLD) exist. We simultaneously assessed the serum and fecal BA patterns in...
9.
Ozaki A, Kessoku T, Tanaka K, Yamamoto A, Takahashi K, Takeda Y, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565243
Opioid-induced constipation (OIC) may occur in patients receiving opioid treatment, decreasing their quality of life (QOL). We compared the effectiveness of magnesium oxide (MgO) with that of naldemedine (NAL) in...
10.
Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, et al.
Front Endocrinol (Lausanne)
. 2021 Nov;
12:770986.
PMID: 34777261
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. It occurs with a prevalence of up to 25%, of which 10-20% cases progress to nonalcoholic steatohepatitis...